These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37641582)

  • 1. A donor safety evidence literature review of the short- and long-term effects of plasmapheresis.
    Hoad VC; Castrén J; Norda R; Pink J
    Vox Sang; 2024 Feb; 119(2):94-101. PubMed ID: 37641582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Offering new and returned donors the option to give plasma: implications for donor retention and donor adverse events.
    Thijsen A; Davison TE; Speedy J; Hoad V; Masser B
    Vox Sang; 2021 Mar; 116(3):273-280. PubMed ID: 32702163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres.
    Crocco I; Franchini M; Garozzo G; Gandini AR; Gandini G; Bonomo P; Aprili G
    Blood Transfus; 2009 Jan; 7(1):35-8. PubMed ID: 19290078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volunteer donor apheresis.
    Waxman DA
    Ther Apher; 2002 Feb; 6(1):77-81. PubMed ID: 11886580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of immediate adverse effects associated with apheresis donation.
    McLeod BC; Price TH; Owen H; Ciavarella D; Sniecinski I; Randels MJ; Smith JW
    Transfusion; 1998 Oct; 38(10):938-43. PubMed ID: 9767744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor vigilance data of a blood transfusion service: A multicenter analysis.
    Burkhardt T; Dimanski B; Karl R; Sievert U; Karl A; Hübler C; Tonn T; Sopvinik I; Ertl H; Moog R
    Transfus Apher Sci; 2015 Oct; 53(2):180-4. PubMed ID: 26074050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications of donor apheresis.
    Winters JL
    J Clin Apher; 2006 Jul; 21(2):132-41. PubMed ID: 15880355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor safety in an individualized plasmapheresis program - Results of an interim analysis.
    Taborski U; Laitinen T
    Transfus Apher Sci; 2022 Oct; 61(5):103446. PubMed ID: 35461780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Canadian Red Cross plasmapheresis donor safety program: changes in plasma proteins after long-term plasmapheresis.
    Wasi S; Santowski T; Murray SA; Perrault RA; Gill P
    Vox Sang; 1991; 60(2):82-7. PubMed ID: 2031342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin G levels during collection of large volume plasma for fractionation.
    Burkhardt T; Rothe R; Moog R
    Transfus Apher Sci; 2017 Jun; 56(3):417-420. PubMed ID: 28454884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Plasma Unit Weight and Donor Sex on Post-Donation Citrate Level: An Experimental Study on Plasmapheresis Donors.
    Marraccini C; Schiroli D; Mancuso P; Molinari G; Razzoli A; Gavioli G; Fasano T; Baricchi R; Rossi PG; Merolle L
    Transfus Med Hemother; 2023 Dec; 50(6):491-501. PubMed ID: 38089491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bradykinin production during donor plasmapheresis procedures.
    Perseghin P; Capra M; Baldini V; Sciorelli G
    Vox Sang; 2001 Jul; 81(1):24-8. PubMed ID: 11520412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of saline infusion and citrate infusion rate during donor plasmapheresis.
    Evers J; Schreiber GB; Taborski U
    J Clin Apher; 2022 Dec; 37(6):584-591. PubMed ID: 36314778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for acute, moderate to severe donor reactions associated with multicomponent apheresis collections.
    Yuan S; Gornbein J; Smeltzer B; Ziman AF; Lu Q; Goldfinger D
    Transfusion; 2008 Jun; 48(6):1213-9. PubMed ID: 18346014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apheresis affects bone and mineral metabolism.
    Amrein K; Katschnig C; Sipurzynski S; Stojakovic T; Lanzer G; Stach E; Pieber TR; Dobnig H
    Bone; 2010 Mar; 46(3):789-95. PubMed ID: 19922822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of RBC apheresis and whole blood donation in allogeneic and autologous blood donors.
    Popovsky MA
    Transfus Apher Sci; 2006 Apr; 34(2):205-11. PubMed ID: 16513425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers.
    Tran-Mi B; Storch H; Seidel K; Schulzki T; Haubelt H; Anders C; Nagel D; Siegler KE; Vogt A; Seiler D; Hellstern P
    Vox Sang; 2004 Apr; 86(3):189-97. PubMed ID: 15078254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Citrate anticoagulation: Are blood donors donating bone?
    Bialkowski W; Bruhn R; Edgren G; Papanek P
    J Clin Apher; 2016 Oct; 31(5):459-63. PubMed ID: 26607494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal blood volume of donors during automated intermittent-flow plasmapheresis and its relevance to the prevention of circulatory reactions.
    Karger R; Slonka J; Junck H; Kretschmer V
    Transfusion; 2003 Aug; 43(8):1096-106. PubMed ID: 12869116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taking therapeutic apheresis services to patients in South Africa: An eight year review of SANBS mobile therapeutic apheresis service, 2013-2020.
    Poole C; Strydom C; van der Berg K; Vrielink H
    Transfus Apher Sci; 2021 Jun; 60(3):103167. PubMed ID: 34116933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.